One such therapy is a combination of two immunotherapies: the immune checkpoint inhibitor, anti-PD-1, and a CC-chemokine receptor-2 (CCR2) antagonist that prevents the tumor-induced recruitment of immunosuppressive myeloid-derived suppressor cells (MDSCs). The gene discussed is CCR2; the disease is neoplasm.